Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: A retrospective analysis

Bone Marrow Transplantation

Volumn 18, Issue 1, 1996, Pages 93-102

  Peters, B G ^a   Adkins, D R ^b,c   Harrison, B R ^b   Velasquez, W S ^b   Dunphy, F R ^b   Petruska, P J ^b   Bowers, C E ^b   Niemeyer, R ^b   McIntyre, W ^b   Vrahnos, D ^b   Auberry, S E ^a   Spitzer, G ^b,d  

^a SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

^b S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LDS HOSPITAL   (United States)

Author keywords

Antifungal agents; Autologous transplantation; GM CSF; High dose therapy

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 3; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTIFUNGAL ACTIVITY; ARTICLE; AUTOTRANSPLANTATION; CANCER; CANCER CHEMOTHERAPY; FEMALE; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MYCOSIS; NEUTROPHIL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STEM CELL TRANSPLANTATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; DISEASE SUSCEPTIBILITY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; INCIDENCE; INTERLEUKIN-3; MALE; MIDDLE AGED; MYCOSES; NEOPLASMS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 9544249373     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Zimmerman LE. Fatal fungus infections complicating other illnesses. Am J Clin Pathol 1955; 25: 46-65.
2. Barker RD. Leukopenia and therapy in leukemia as factors predisposing to fatal mycoses. Am J Clin Pathol 1962; 37: 358-363.
3. Mirsky HS, Cuttner J. Fungal infections in acute leukemia. Cancer 1972; 30: 348-352.
4. Singer C, Kaplan MH, Armstrong D. Bacteremia and fungemia complicating neoplastic disease. Am J Med 1973; 54: 6-15.
5. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17 (Suppl. 6): 10-13.
6. Wiley JM, Smith N, Leventhal BG et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol 1990; 8: 280-296.
7. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-110.
8. Pirsch JD, Maki DG. Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Ann Intern Med 1986; 104: 619-631.
9. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in the febrile granulocytopenic patients. Am J Med 1989; 86: 668-672.
10. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992; 14 (Suppl. 1): S43-53.
11. Meunier-Carpentier F, Kiehn TE, Armstrong D. Fungemia in the immunocompromised host. Am J Med 1981; 71: 363-370.
12. Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985; 7: 646-655.
13. Young RC, Bennett JE, Geelhoed GW, Levine AS. Fungemia with compromised host resistance. Ann Intern Med 1974; 80: 605-612.
14. Hughes WT, Armstrong D, Bodey GP et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161: 381-396.
15. Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis 1994; 18: 273-284.
16. Wingard JR. Advances in the management of infectious complications after bone marrow transplantation. Bone Marrow Transplant 1990, 6: 371-383.
17. Wingard JR, Merz WG, Rinaldi MG et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37: 1847-1849.
18. Merz WG, Karp JE, Schron D, Saral R. Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol 1986; 24: 581-584.
19. Bodey GP. Fungal infections complicating acute leukemia. J Chronic Dis 1966; 19: 667-687.
20. Torack MR. Fungus infections associated with antibiotic and steroid therapy. Am J Med 1957; 22: 872-882.
21. Schwartz RS, Mackintosh FR, Schrier SL et al. Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer 1984; 53: 411-419.
22. Dato VM, Dajani AS. Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy. Pediatr Infect Dis J 1990; 9: 309-314.
23. Meyers JD, Thomas ED. Infection complicating bone marrow transplantation. In: Rubin RH, Young LS (eds). Clinical Approach to Infection in the Immunocompromised Host. Plenum Press: New York, 1982, pp 507-551.
24. Tollemar J, Ringden O, Bostrom L et al. Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1989; 4: 635-641.
25. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326: 845-851.
26. Hann IM, Corringham R, Keaney M et al. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1982; 1: 826-829.
27. Degregorio MW, Lee WM, Linker CA et al. Fungal infections in patients with acute leukemia. Am J Med 1982; 73: 543-548.
28. Sherertz RJ, Belani A, Kramer BS et al. Impact of air filtration on nosocomial aspergillus infections. Am J Med 1987; 83: 709-718.
29. Brandt SJ, Peters WP, Atwater SK et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. New Engl J Med 1988; 318: 869-876.
30. Nemunaitis J, Singer JW, Buckner CD et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. Blood 1988; 72: 834-836.
31. Peters WP. The effect of recombinant human colony-stimulating factors on hematopoietic reconstitution following autologous bone marrow transplantation. Semin Hematol 1989; 26: 18-24.
32. Gianni AM, Bregni M, Siena S et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990; 8: 768-778.
33. Smith PD, Lamerson CL, Banks SM et al. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. J Infect Dis 1990; 161: 999-1005.
34. Mayer P, Schütze E, Lam C, Kricek F. Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice. J Infect Dis 1991; 163: 584-590.
35. Wang M, Friedman H, Djeu JY. Enhancement of human monocyte function against Candida albicans by the colony-stimulating factors (CSF): IL-3, granulocyte-macrophage-CSF, and macrophage-CSF. J Immunol 1989; 143: 671-677.
36. Karbassi A, Becker JM, Foster JS et al. Enhanced killing of Candida albicans by murine macrophages treated with macrophage colony-stimulating factor: evidence for augmented expression of mannose receptors. J Immunol 1987; 139: 417-421.
37. Cenci E, Bartocci A, Puccetti P et al. Macrophage colony-stimulating factor in murine candidasis: serum and tissue levels during infection and protective effect of exogenous administration. Infect Immunol 1991; 59: 868-872.
38. Schuit KE. Phagocytosis and intracellular killing of pathogenic yeast by human monocytes and neutrophils. Infect Immunol 1979; 24: 932-938.
39. Leijh PCJ, van den Barselaar MT, van Furth R. Kinetics of phagocytosis and intracellular killing of Candida albicans by human granulocytes and monocytes. Infect Immunol 1977; 17: 313-318.
40. Kowanko IC, Ferrante A, Harvey DP, Carman KL. Granulocyte-macrophage colony-stimulating factor aguments neutrophil killing of Torulopsis glabrata and stimulates neutrophil respiratory burst and degranulation. Clin Exp Immunol 1991; 83: 225-230.
41. Collins HL, Bancroft GJ. Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-a and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neoformans. Eur J Immunol 1992; 22: 1447-1454.
42. Roilides E, Carter C, Holmes A et al. Interferon γ (IFN-γ) and granulocyte-macrophage colony-stimulating factor (GM-CSF) enhance the fungicidal activity of normal and dexamethasone (DXS)-treated elutriated human monocytes (MNCs) against Aspergillus. Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, USA, October 1992. 1992, 121: (Abstr. No. 65).
43. Lechner AJ, Lamprech KE, Pottfoff LH et al. Recombinant GM-CSF reduces lung injury and mortality during neutropenic. Candida sepsis. Am J Physiol: Lung Cell Mol Physiol 1994; 266: L561-568.
44. Roilides E, Walsh TJ, Pizzo PA, Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991; 163: 579-583.
45. Djeu JY. Role of tumor necrosis factor and colony-stimulating factors in phagocyte function against Candida albicans. Diagn Microbiol Infect Dis 1990; 13: 383-386.
46. Bodey GP, Anaissie E, Gutterman J. Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993; 17: 705-707.
47. Bodey GP. The potential role of granulocyte-macrophage colony stimulating factor in therapy of fungal infections: a commentary. Eur J Clin Microbiol Infect Dis 1994; 13: 363-366.
48. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. Lifetime Learning Publications: Belmont, CA, 1982.
49. Dunphy FR, Spitzer G, Buzdar AU et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207-1216.
50. Neidhart J, Kohker W, Stidley C et al. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide and cisplatin administered without bone marrow transplantation. J Clin Oncol 1990; 8: 1728-1738.
51. Huan SD, Yau JC, Dunphy FR et al. Impact of autologous bone marrow infusion on the hematopoietic recovery following high-dose cyclophosphamide, etoposide and cisplatin. J Clin Oncol 1991; 9: 1609-1617.
52. Huan SD, Hester J, Spitzer G et al. Influence of mobilized peripheral blood cells on the hematopoietic recovery by autologous marrow and recombinant granulocyte-macrophage colony-stimulating factor following high-dose cyclophosphamide, etoposide and cisplatin. Blood 1992; 79: 3388-3393.
53. Vellekoop L, Jagannath S, Spitzer G et al. High-dose cyclophosphamide, BCNU, and etoposide followed by autologous bone marrow rescue as treatment for adult acute leukemia in relapse. Am J Clin Oncol 1986; 9: 307-310.
54. Jagannath S, Armitage JO, Dicke KA et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow trans-plantation for relapsed Hodgkin's disease. J Clin Oncol 1989; 7: 179-185.
55. Wheeler JH, Antin W, Hallowell C et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8: 648-656.
56. Vellekoop L, Dicke KA, Zander AR et al. Repeated high-dose cyclophosphamide 1,3-bis-2 chloroethyl-1-nitrosourea and VP-16-213 etoposide and autologous bone marrow transplantation in adult acute lymphocytic leukemia in first remission. Eur J Cancer Clin Oncol 1984; 20: 593-600.
57. Bitran JD, Williams SK. High-dose chemotherapy with cyclophosphamide and thiotepa with autologous marrow reinfusion. Is there a role for this therapy in the treatment of Stage IV breast cancer? In: Herzig GP (Chairman). High Dose Thiotepa and Autologous Marrow Transplantation, Proceedings of a Symposium. Dallas, TX, 1986, pp 39-42.
58. Nichols CR, Tricot G, Williams SD et al. Dose intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose carboplatin and etoposide with bone marrow transplantation. J Clin Oncol 1989; 7: 932-939.
59. Wallerstein J, Spitzer G, Dunphy FR et al. A phase II study of mitoxantrone, etoposide (VP-16), and thiotepa (MVT) with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol 1990; 8: 1782-1788.
60. Champlin R, Jacobs A, Gale RP et al. High-dose cytarabine in combination chemotherapy as with bone marrow transplantation for patients with acute leukemia. Semin Oncol 1985; 12: 190-195.